Clinical Trials
91 trialsNCT02750202 2026-01-23
TheraVACCS
University of Pretoria
Phase 3 Completed
NCT06756269 2025-12-17
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 2 Recruiting
NCT04537156 2025-11-21
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Xiamen University
Phase 3 Active not recruiting
NCT05087849 2025-10-02
Intralesional HPV Vaccine for Condylomata
University of California, San Francisco
Phase 1/2 Completed
NCT02520986 2025-08-19
Carbon Dioxide Laser vs. Electrocoagulation for the Therapy of Condyloma
Zydolab - Institute of Cytology and Immune Cytochemistry
Phase NA Recruiting
NCT04635423 2025-08-11
V503-064
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00092534 2025-08-01
FUTURE II
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06866574 2025-07-31
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Xiamen University
Phase 3 Active not recruiting
NCT05056402 2025-07-22
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
Xiamen University
Phase 3 Active not recruiting
NCT06809777 2025-05-13
Comparison Between Efficacy of Topical 25%Podophyllin and Cryotherapy on Genital Warts
Sheikh Zayed Medical College
Phase 2 Not yet recruiting
NCT02377999 2025-02-24
Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts
LEO Pharma
Phase 2 Completed
NCT06454175 2025-01-06
A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 1 Active not recruiting
NCT06465914 2024-12-12
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Active not recruiting
NCT03981822 2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT06681636 2024-11-08
HPV9vxFSW
National Institute of Hygiene and Epidemiology, Vietnam
Phase 2 Not yet recruiting
NCT06587542 2024-09-19
Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV Patient
Universitas Padjadjaran
Phase 2/3 Not yet recruiting
NCT06430190 2024-06-20
Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata
First People's Hospital of Hangzhou
Phase NA Not yet recruiting
NCT04422366 2024-06-07
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Recruiting
NCT04895020 2024-04-17
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Recruiting
NCT05027776 2024-04-17
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Recruiting
NCT05518201 2024-04-17
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
Shanghai Bovax Biotechnology Co., Ltd.
Phase 1 Completed
NCT06281353 2024-02-28
The Effect of Oral Nanocurcumin as an Adjuvant Therapy for Anogenital Warts: Evaluation of Clinical Improvement, NFĸB, IFN-γ, and FOXP3+TReg From Lesions Tissue
Indonesia University
Phase 2/3 Completed
NCT05372016 2023-11-24
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Completed
NCT05584332 2023-07-21
A Phase â…¢ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Terminated
NCT02710851 2023-06-15
Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
Xiamen University
Phase 2 Unknown
NCT04782895 2023-06-15
Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age
Xiamen University
Phase 3 Completed
NCT03900572 2023-04-13
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
Shanghai Zerun Biotechnology Co.,Ltd
Phase 1 Completed
NCT02462187 2023-04-06
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
Novan, Inc.
Phase 2 Completed
NCT05761002 2023-03-09
Human Papilloma Virus Genotypes and Treatment Outcomes of Intralesional Immunotherapy of Anogenital Warts
Zagazig University
Phase NA Unknown
NCT00973856 2023-01-31
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
Cleveland Clinic Akron General
Phase NA Completed
NCT05694728 2023-01-23
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 2 Completed
NCT05314023 2023-01-19
V503-053
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05680454 2023-01-17
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 1 Completed
NCT05662020 2022-12-27
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Beijing Health Guard Biotechnology, Inc
Phase 3 Active not recruiting
NCT05622916 2022-11-21
Topical Ethanol Extract (Piper Crocatum) for Anogenital Warts
Hasanuddin University
Phase NA Unknown
NCT05580341 2022-10-28
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
Shanghai Zerun Biotechnology Co.,Ltd
Phase 3 Unknown
NCT02405520 2022-05-24
Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
Xiamen University
Phase 1 Completed
NCT04425291 2022-02-25
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Completed
NCT00189293 2022-02-07
Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
Viatris Inc.
Phase 4 Completed
NCT05156541 2021-12-14
ING-HPV-1
SPP Pharmaclon Ltd.
Phase 3 Completed
NCT04905030 2021-06-11
Education, Immigration and HPV Vaccination: an Informational Randomized Trial
Karolinska Institutet
Phase NA Unknown
NCT03158974 2021-05-03
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of External Genital Warts
ViroXis Corporation
Phase 2 Terminated
NCT03813940 2021-04-08
Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Xiamen University
Phase 1 Completed
NCT03935204 2021-04-08
Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Xiamen University
Phase 2 Completed
NCT02482428 2021-01-05
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
Phase 2 Completed
NCT03289260 2020-09-23
AdAM
Medical University Innsbruck
Phase 3 Unknown
NCT03546842 2020-02-25
V503-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01796821 2020-02-05
Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)
G&E Herbal Biotechnology Co., LTD
Phase 2 Completed
NCT03676101 2020-01-22
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Shanghai Bovax Biotechnology Co., Ltd.
Phase 1 Completed
NCT03158220 2019-11-21
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Merck Sharp & Dohme LLC
Phase 3 Completed